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Heart failureMyocardial energy expenditure (MEE) and 2-oxoglutarate are elevated in chronic heart failure (CHF) patients
compared with healthy controls. To explore whether 2-oxoglutarate could reﬂect the levels of MEE and predict
the prognosis of CHF, 219 CHF patients and 66 healthy controls were enrolled. 2-Oxoglutarate was assayed
with Liquid Chromatography–Mass Spectrometry/Mass Spectrometry (LC/MS/MS). CHF patients were divided
into 4 groups according to interquartile range of MEE and followed for death or recurrent hospital admission
due to CHF for themean follow-up time 6.64± 0.16 months. 2-Oxoglutarate was increased in CHF patients com-
pared with controls (P b 0.01) and correlated with estimated glomerular ﬁltration rate (r = 0.142, P= 0.036),
age (r =−0.269, P b 0.01) and MEE levels (r = 0.307, P b 0.01) in a multiple linear correlation analysis in CHF
patients. Furthermore, 2-oxoglutarate (OR = 3.470, 95% CI = 1.557 to 7.730, P= 0.002), N-terminal pro-B-type
natriuretic peptide (OR = 4.013, 95% CI = 1.553 to 10.365, P = 0.004), age (OR = 1.611, 95% CI = 1.136 to
2.283, P= 0.007) and left ventricular ejection fraction (OR= 7.272, 95% CI= 3.110 to 17.000, P b 0.001) were in-
dependently associated withMEE onmultiple logistic regression analysis. Kaplan–Meier event curves showed that
high 2-oxoglutarate levels were associatedwith adverse outcomes (Log Rank, Chi2= 4.026, P= 0.045). This study
showed that serum 2-oxoglutarate is associated with MEE levels, which can be used as potential biomarkers for
MEE, and it can reﬂect the clinical severity and short-term outcome of CHF.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Heart failure (HF) is a complex syndrome characterized bymechanical
dysfunction of the myocardium, abnormal metabolism and excessive,
continuous neurohormonal activation [1]. Several myocardial metabolic
abnormalities occur in chronic heart failure (CHF), including altered
substrate utilization and decreased high energy phosphate content [2].
Despite recent great progress, the knowledge of metabolic abnormalities
in CHF is still limited. Whether and how they alter according to etiology
and the severity of CHF remain poorly understood.ogy, NanfangHospital, Southern
angzhou, Guangdong 510515,
y, Nanfang Hospital, Southern
angzhou, Guangdong 510515,
glixu@ﬁmmu.com (D.-L. Xu).Recently, studies showed that there were signiﬁcant metabolic
differences in serum [3], urine [4] and exhaled breath [5–7] samples be-
tween CHF patients and the healthy subjects. These ﬁndings suggested
that some metabolites may associate with CHF and can reﬂect the
state of cardiac energy metabolism. Of these, 2-oxoglutarate [3], a
major intermediatemetabolite of the tricarboxylic acid cycle, is a prom-
ising one due to its important roles in regulating myocardial energy
metabolism.
Myocardial energy expenditure (MEE) is an important indicator
reﬂecting myocardial energy metabolism. Different ways to estimate
MEE in failing heart were provided in recent years, including positron
emission tomography [8,9], nuclear magnetic resonance [10,11] and
Doppler echocardiography [12,13]. It has been reported that elevated
MEE is associated with decreased left ventricular ejection fraction
(LVEF) and can be used as an independent predictor of cardiovascular
mortality [12]. Recently, our preliminary results showed that in patients
with CHF, elevation of MEE was associated with signiﬁcant changes in
serum metabolomic proﬁles by 1H-NMR-based metabolic analysis and
2121P.-A. Chen et al. / Biochimica et Biophysica Acta 1842 (2014) 2120–2125suggested that these compounds could be used as potential serum
biomarkers to explore myocardial energy mechanism in CHF patients
[14].
The purpose of this study was to evaluate the relationship between
2-oxoglutarate and MEE in CHF patients. Our goals were: 1) to test the
hypotheses that whether the serum concentration of 2-oxoglutarate is
associated with MEE levels and can reﬂect the severity of CHF; and 2)
to assess the predictive value of 2-oxoglutarate for the prognosis of CHF.
2. Materials and methods
2.1. Study population
219 patients with CHF were consecutively enrolled after obtaining
informed consent in 2 participating centers (Nanfang Hospital and
Guangzhou First People's Hospital, China). Patients with acute coronary
syndrome, diabetes mellitus and other metabolic diseases, estimated
glomerular ﬁltration rate (eGFR) b 30 mL/min/1.73 m2, sepsis, malig-
nancy, autoimmune disease or severe hepatic disease were excluded.
The underlying causes of CHF were classiﬁed as hypertension, ischemic
heart disease, valvular heart disease and dilated cardiomyopathy on
the basis of the patients' history, cardiac morphology and coronary angi-
ography. Consensus of 2 experienced clinical cardiologists was required
for the classiﬁcation of New York Heart Association (NYHA) functional
classes. The severity of CHF was evaluated by NYHA classiﬁcation and
MEE. Follow-up events, including all-cause mortality and recurrent
hospital admission due to CHF, were ascertained via hospital database,
medical records and contact with patients and their family members.
Sixty-six age-matched control subjects with normal cardiac function
were recruited from the health management center and outpatient de-
partment in Guangzhou First People's Hospital. The study complied
with the Declaration of Helsinki and was approved by the institutional
ethics committee of Nanfang Hospital and Guangzhou First People's
Hospital, China. All subjects were providedwith a hard copy of informed
consent before recruitment.
2.2. Biochemistry detection
Antecubital venous bloodwas drawn into pyrogen-free tubes with or
without EDTA as anticoagulant respectively on the same day of MEE
measurement. After centrifugation at 3000 g at 4 °C for 10 min, all
serum or platelet-poor plasma samples were stored at−80 °C. Serum
2-oxoglutarate was assayed with Agilent 6460 LC/MS/MS (USA).
Chromatographic separations of prepared samples were achieved using
an Eclipse Plus C 18 column (3.5 μm, 2.1mm× 100mm). Themass spec-
trometer was operated in the positive ion ESI mode with MRM for the
analytes. The following optimized ESI parameters were applied: drying
gas ﬂow rate, 10 L/min; drying gas temperature, 350 °C; nebulizing gas
pressure 30 psi; capillary voltage 4000 V; and fragmentor voltage 50 V.
Free thyroxine, free triiodothyronine and thyroid stimulating hormone
(TSH) were measured with a direct chemiluminescence immunoassay
(Siemens Healthcare Diagnostics Inc., USA). N-terminal pro-B-type natri-
uretic peptide (NT-proBNP) was analyzed with the Elecsys NT-proBNP
immunoassay (Roche Diagnostics). Estimated glomerular ﬁltration rate
(eGFR) was calculated based on MDRD formula. All subjects underwent
oral glucose tolerance test (OGTT) with 75 g of oral anhydrous glucose
as described previously [15].
2.3. MEE measurement
MEE was measured with a Siemens Sequoia 512 Encompass ultra-
sound system, using the method described previously [12,16]. Systolic
blood pressure (SBP), left ventricular internal diameter at systole
(LVIDs), left ventricular posterior wall end-systolic thickness (PWTs),
left ventricular ejection time (LVET), LVEF and left ventricular stroke
volume (LVSV) were measured. Finally, MEE was calculated as [12,16]: MEE (cal/min) = left ventricular circumferential end-systolic wall
stress (cESS) × LVET × LVSV × heart rate × 4.2 × 10−4.
cESS ¼




LVIDs=2þ PWTsð Þ2− LVIDs=2ð Þ2
2.4. Statistical analysis
The continuous normal variables were expressed asmean± SD, and
medians were presented with the 25th to 75th percentiles for skewed
continuous variables. CHF patients were divided into quartiles on the
basis of the levels of MEE. Categorical variables were compared with
Pearson's χ2 test. Differences between mean or median values for con-
tinuous variables were evaluated with Kruskall–Wallis test or 1-way
ANOVA with S–N–K analysis, as appropriate. Pearson correlation for
the normal and logarithmically transformed skewed variables was
used to assess associations between study parameters. Multicollinearity
(strong correlations among independent variables) was examined
by collinearity diagnostic statistics. Variance inﬂation factor (VIF)
values N 4.0 or tolerance b 0.25 may indicate a concern for multi-
collinearity in multivariate regression models [17]. The concentrations
of 2-oxoglutarate were skewed and thus, were logarithmically trans-
formed (Log 2-oxoglutarate) for calculation of associations with
biochemical parameters (fasting blood glucose, postprandial blood
glucose, hemoglobin A1c, alanine aminotransferase, aspartate amino-
transferase) and other clinical parameters (NT-proBNP, eGFR, NYHA
classiﬁcation, LVEF, age, sex andMEE) in Pearson correlation andmulti-
ple linear regression analysis. Multivariable logistic regression analysis
was used to investigate associations between MEE levels (dependent
variable) and other parameters (independent variables) including
fasting blood glucose, postprandial blood glucose, hemoglobin A1c,
age, sex, creatinine, eGFR, 2-oxoglutarate, NYHA classiﬁcation, free
triiodothyronine, free thyroxine, thyroid-stimulating hormone, body
mass index, LVEF and NT-proBNP. Events of recurrent hospital admission
due to CHF or death in 8 months were investigated with Kaplan–Meier
analysis by Log rank test. P values were two-sided and considered signif-
icantwhen b0.05. Statistical analyseswere carried out using the software
package SPSS version 17.0 (SPSS Inc., Chicago, IL).
3. Results
3.1. Baseline characteristics
Serum 2-oxoglutarate was higher in CHF patients compared
with controls (median, 13.02 μg/mL [IQR 6.14 to 26.89] versus
10.58 μg/mL [IQR 7.69 to 13.42], P b 0.01). Patients with CHF were
divided into 4 groups according to the interquartile range of MEE.
Those with a MEE b 59.51 cal/min were included in the MEE 1
group; 59.51 cal/min ≤ MEE b 99.94 cal/min in the MEE 2 group;
99.94 cal/min ≤ MEE b 184.18 cal/min in the MEE 3 group; and
MEE ≥ 184.18 cal/min in the MEE 4 group. Basic characteristics of
4 groups were presented in Table 1. Clinical parameters in 4 groups
were similar except for higher NT-proBNP, left ventricular mass
index (LVMI), Tei index, NYHA classes, as well as lower free triiodo-
thyronine and high-density lipoprotein in the MEE 4 group com-
pared with the MEE 1 group. Patients belonging to NYHA classes III
and IV were with signiﬁcantly higher MEE values than class I and II
patients. NYHA classes were higher with greater MEE (Fig. 1).
Serum 2-oxoglutarate levels were lower in the MEE 1 group than
those in the MEE 3 and 4 groups (both P b 0.01). Compared with the
MEE 3 and 4 groups, the similar results were found in the MEE 2
group (both P b 0.05). However, there were no signiﬁcant differences
Table 1












Age, years 60.64 ± 10.62 64.02 ± 12.39 61.87 ± 9.98 64.93 ± 10.03 62.95 ± 12.30 0.239
Female, n (%) 29 (43.94%) 29 (52.73%) 27 (49.09%) 19 (35.19%) 17 (30.91%) 0.108
Causes of CHF
Hypertension, n (%) – 28 (50.91%) 29 (52.73%) 23 (42.59%) 22 (40.00%) 0.466
Ischemic heart disease, n (%) – 25 (45.45%) 25 (45.45%) 28 (51.85%) 29 (52.73%) 0.793
Valvular heart diseases, n (%) – 9 (16.36%) 6 (10.91%) 6 (11.11%) 6 (10.91%) 0.775
Dilated cardiomyopathy, n (%) – 2 (3.64%) 3 (5.45%) 8 (14.81%) 7 (12.73%) 0.119
Medication use
ACE inhibitors or ARBs, n (%) – 26 (47.27%) 26 (47.27%) 22 (40.74%) 40 (72.73%) b0.010
Aldosterone antagonists, n (%) – 19 (34.55%) 20 (36.36%) 31 (57.41%) 43 (78.18%) b0.010
Aspirin, n (%) – 24 (43.64%) 27 (49.09%) 31 (57.41%) 31 (56.36%) 0.429
Beta–blockers, n (%) – 23 (41.82%) 22 (40.00%) 26 (48.15%) 32 (58.18%) 0.216
Diuretics, n (%) – 32 (58.18%) 27 (49.09%) 35 (64.81%) 45 (81.82%) b0.010
Digitalis, n (%) – 12 (21.82%) 10 (18.18%) 15 (27.78%) 21 (38.18%) 0.091
Statin, n (%) – 24 (43.64%) 22 (40.00%) 27 (50.00%) 26 (47.27%) 0.890
Clinical measures
NYHA class I, n (%) 66 (100%) 16 (29.09%) 22 (40.00%) 4 (7.41%) 0 b0.010
NYHA class II, n (%) 0 14 (25.45%) 10 (18.18%) 18 (33.33%) 7 (12.73%) 0.033
NYHA class III, n (%) 0 13 (23.64%) 14 (25.45%) 17 (31.48%) 26 (47.27%) 0.033
NYHA class IV, n (%) 0 12 (21.82%) 9 (16.36%) 15 (27.78%) 22 (40.00%) 0.071
LVEF b 45%, n (%) 0 4 (7.27%) 9 (16.36%) 22 (40.74%) 38 (69.09%) b0.010
LVEF ≥ 45%, n (%) 66 (100%) 51 (92.73%) 46 (83.64%) 32 (59.26%) 17 (30.91%) b0.010
Body mass index, kg/m2 23.17 ± 2.86 22.08 ± 2.71 23.49 ± 3.12 23.21 ± 2.77 22.88 ± 2.89 0.797
Creatinine, μmol/L 101.94 ± 17.22 107.31 ± 43.27 107.49 ± 53.17 117.04 ± 39.49 124.92 ± 63.55 0.053
eGFR, mL/min/1.73 m2 69.04 ± 16.62 61.47 ± 22.54 65.06 ± 24.06 58.77 ± 19.89 59.89 ± 23.08 0.053
Free triiodothyronine, pmol/L – 3.73 ± 0.97 3.86 ± 1.27 3.50 ± 0.99 3.15 ± 0.92† b0.010
Free thyroxine, pmol/L – 15.67 ± 3.89 15.82 ± 3.76 15.81 ± 3.53 15.28 ± 3.64 0.860
TSH, uIU/L – 2.21 ± 1.53 1.93 ± 1.69 2.18 ± 1.86 2.50 ± 2.63 0.506
Fasting blood glucose, mmol/L 5.20 ± 0.65 5.23 ± 1.09 5.39 ± 1.27 5.29 ± 1.14 5.31 ± 1.57 0.923
2 h PBG, mmol/L 6.87 ± 0.80 7.66 ± 2.61⁎ 7.84 ± 2.34⁎ 8.18 ± 2.60⁎ 8.06 ± 2.66⁎ 0.013
Hemoglobin A1c, % 5.80 (5.50–6.00) 5.80 (5.50–6.20) 5.70 (5.40–6.20) 5.95 (5.68–6.23) 5.90 (5.60–6.40) 0.056
Total cholesterol, mmol/L 4.99 ± 0.38 4.17 ± 0.94⁎ 4.26 ± 1.16⁎ 4.07 ± 1.06⁎ 4.43 ± 1.16⁎ b0.010
LDL, mmol/L 2.74 ± 0.51 2.43 ± 0.63 2.48 ± 0.92 2.55 ± 0.83 2.82 ± 0.91 0.059
Triglyceride, mmol/L 1.33 ± 0.32 1.24 ± 0.67 1.61 ± 1.19 1.27 ± 0.94 1.30 ± 0.56 0.095
HDL, mmol/L 1.05 ± 0.18 1.12 ± 0.46 1.02 ± 0.29 0.94 ± 0.25⁎,# 0.96 ± 0.27⁎,# 0.010
Aspartate aminotransferase, U/L 26 (20–38) 26 (19–37) 26 (19–38) 26 (18–43) 27 (21–37) 0.298
Alanine aminotransferase, U/L 19 (12–28) 16 (11–23) 17 (10–25) 20 (12–36) 19 (12–31) 0.055
Hematoglobin, g/L 122.62 ± 6.79 124.72 ± 16.97 123.20 ± 18.29 128.67 ± 21.38 126.85 ± 20.49 0.122
LVMI, g/m2 79 (70–98) 81 (71–106) 97 (80–135)⁎,# 123 (103–152)⁎,#,† 165 (132–205)⁎,#,† b0.010
Tei index 0.49 (0.40–0.56) 0.63 (0.58–0.84)⁎ 0.60 (0.53–0.75)⁎ 0.83 (0.67–0.94)⁎,† 0.92 (0.72–1.14)⁎,† b0.010
LVEF, % 58 (55–61) 57 (52–61) 58 (52–62) 47 (35–56)⁎,# 38 (29–51)⁎,# b0.010
MEE, cal/min 46 (36–57) 41 (34–52) 80 (69–92)⁎,# 128 (112–153)⁎,#,† 276 (225–397)⁎,#,† b0.010
NT-proBNP, pg/mL 78 (57–106) 1393 (187–3946)⁎ 1212 (175–4110)⁎ 4603 (1834–10033)⁎,#,† 7662 (4128–21671)⁎,#,† b0.010
2-Oxoglutarate, μg/mL 10.58 (7.69–13.42) 8.92 (4.81–16.46) 11.43 (5.65–18.42) 16.75 (9.44–28.56)⁎,#,† 26.25 (12.42–30.45)⁎,#,† b0.010
Data aremean ± SD, ormedian (interquartile range). Abbreviations: CHF, chronic heart failure; MEE,myocardial energy expenditure; ACE, angiotensin converting enzyme; ARB,
angiotensin receptor blocker; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; eGFR, estimated glomerular ﬁltration rate; TSH, thyroid-stimulating hormone;
PBG, postprandial blood glucose; LDL, low density lipoprotein; HDL, high density lipoprotein; LVMI, left ventricular mass index; NT-proBNP, N-terminal pro-B-type natriuretic peptide.
⁎ Vs control group, P b 0.05.
# Vs MEE 1 group, P b 0.05.
† Vs MEE 2 group, P b 0.05.
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(Table 1).
3.2. Associations between clinical factors and 2-oxoglutarate
Logarithmically transformed 2-oxoglutarate (Log 2-oxoglutarate)
levels were used for calculation of associations with biochemical
parameters and other clinical parameters in Pearson correlation and
multiple linear regression analysis. Pearson correlation showed that
Log 2-oxoglutarate was signiﬁcantly correlated with Log NT-proBNP
(r= 0.283, P b 0.01), eGFR (r= 0.142, P= 0.036), NYHA classiﬁcation
(r = 0.284, P b 0.01) and Log MEE (r = 0.307, P b 0.01), inversely
correlated with age (r =−0.269, P b 0.01) and Log LVEF (r =−0.192,
P b 0.01). Multiple linear regression found that concentrations of
2-oxoglutarate were signiﬁcantly correlated with age (B = −1.035,
P = 0.001), eGFR (B = 0.002, P = 0.040), and MEE (B = 0.275,
P = 0.002) (Table 2). Additionally, collinearity statistics were N0.25for tolerance and b3.5 for VIF, suggesting that multicollinearity was
not a concern among the independent variables.3.3. Relationship between MEE and other clinical parameters
To identify the determinant factors of MEE, a multivariate logistic
regression analysis was performed and showed that 2-oxoglutarate
(OR = 3.470, 95% CI = 1.557 to 7.730, P= 0.002), N-terminal pro-B-
type natriuretic peptide (OR = 4.013, 95% CI = 1.553 to 10.365,
P = 0.004), age (OR = 1.611, 95% CI = 1.136 to 2.283, P = 0.007)
and left ventricular ejection fraction (OR = 7.272, 95% CI = 3.110 to
17.000, P b 0.001) were associated with increased MEE (Table 3).
There were no signiﬁcant associations with sex, NYHA classes, fasting
blood glucose, postprandial blood glucose, hemoglobin A1c, creatinine,
eGFR, bodymass index, free triiodothyronine, free thyroxine or thyroid-
stimulating hormone.
Fig. 1. Distribution of NYHA classiﬁcation in different MEE groups.
Table 3
Multivariate logistic regression analysis for the level of MEE.
OR (95% CI) B P value
Sex (female vs male) 1.725 (0.382–3.576) 0.545 0.142
Age (per 10 years) 1.611 (1.136–2.283) 0.477 0.007
NYHA classes (per class) 0.918 (0.574–1.468) −0.085 0.722
2-Oxoglutarate
(b13.0 μg/mL vs ≥13.0 μg/mL)
3.470 (1.557–7.730) 1.244 0.002
NT-proBNP
(b2000 pg/mL vs ≥2000 pg/mL)
4.013 (1.553–10.365) 1.689 0.004
LVEF (≤45% vs N45%) 7.272 (3.110–17.000) 1.984 b0.001
FBG (b5.6 mmol/L vs ≥5.6 mmol/L) 0.658 (0.303–1.427) −0.419 0.289
PBG (b7.8 mmol/L vs ≥7.8 mmol/L) 0.978 (0.473–2.025) −0.022 0.953
HbA1C (b5.6% vs ≥5.6 %) 1.573 (0.764–3.242) 0.453 0.219
Creatinine
(b120 μmol/L vs ≥120 μmol/L)
1.446 (0.514–4.068) 0.369 0.485
eGFR (per 30 mL/min/1.73 m2) 1.235 (0.664–2.298) 0.211 0.504
BMI (b24 kg/m2 vs ≥24 kg/m2) 1.087 (0.578–2.046) 0.084 0.796
Free thyroxine 1.021 (0.907–1.150) 0.021 0.731
Free triiodothyronine 0.824 (0.541–1.256) −0.194 0.368
TSH 1.073 (0.880–1.309) 0.071 0.487
NYHA, New York Heart Association; NT-proBNP, N-terminal pro-B-type natriuretic pep-
tide; LVEF, left ventricular ejection fraction; FBG, fasting blood glucose; PBG, postprandial
blood glucose; HbA1c, hemoglobin A1c; eGFR, estimated glomerular ﬁltration rate; BMI,
body mass index.; TSH, thyroid-stimulating hormone.
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208 patients had clinical follow up data at 8 months, the mean
follow-up duration was 6.64 ± 0.16 months. There were 7 deaths,
52 recurrent hospital admissions due to CHF. According to the median
level of 2-oxoglutarate, Kaplan–Meier event curves for CHF with low
(b13.03 μg/mL) or high (≥13.03 μg/mL) 2-oxoglutarate levels, showed
a signiﬁcant association between high 2-oxoglutarate levels and in-
creased short-term adverse outcomes in CHF (Log Rank, Chi2 = 4.026,
P= 0.045, Fig. 2).4. Discussion
In the present study, we found that the levels of serum 2-
oxoglutarate were elevated in patients with CHF compared with
healthy age-matched controls. Importantly, 2-oxoglutarate levels
increased in CHF patients were closely associated with the elevation
of MEE, independent of NT-proBNP and NYHA classes. Furthermore,
high levels of 2-oxoglutarate were correlated with adverse short-term
events in patients with CHF. These ﬁndings suggest that serum 2-
oxoglutarate could be a potential biomarker of MEE in CHF patients,
and may be involved in the prognosis of CHF.Table 2
Multiple linear regression analysis for serum 2-oxoglutarate.
B (95% CI) SE t P value
Age −1.035 (−1.642 to−0.428) 0.308 −3.361 0.001
Log NT-proBNP 0.089 (−0.013 to 0.190) 0.052 1.715 0.088
Log LVEF 0.165 (−0.272 to 0.603) 0.222 0.745 0.457
eGFR 0.002 (0.000 to 0.005) 0.001 2.061 0.040
Log LVMI −0.215 (−0.609 to 0.179) 0.200 −1.074 0.284
NYHA class 0.060 (−0.012 to 0.132) 0.036 1.650 0.100
Log MEE 0.275 (0.103 to 0.448) 0.088 3.143 0.002
NT-proBNP, N-terminal pro-B-type natriuretic peptide; LVEF, left ventricular ejection
fraction; eGFR, estimated glomerular ﬁltration rate; LVMI, left ventricular mass index;
NYHA, New York Heart Association; MEE, myocardial energy expenditure.4.1. Alterations of MEE in CHF
MEE is a major indicator of myocardial energy metabolism, which is
abnormal in failing heart. A previous study identiﬁed that MEE was an
effective parameter of myocardial bioenergetics and signiﬁcantly corre-
lated with cardiac function in patients with CHF, particularly with
reduced LVEF [16,18]. More importantly, elevated MEE was thought to
be more effective in predicting cardiac death than LVEF [12]. Recently,
our group found that higher doses of perindopril can improve left
ventricular systolic function and decrease MEE further than lower
doses in patients with HF aftermyocardial infarction [19]. In the present
study, we also showed that most patients with high MEE belonged to
NYHA class III or IV. These data supported alterations of MEE in CHF
and suggested that it could be a good indicator for CHF.4.2. The cause of elevation of 2-oxoglutarate in CHF and the relationship
between MEE and 2-oxoglutarate
It has been reported that a metabolic shift from free fatty acid to
glucose as a preferred substrate in CHF existed [20,21].When the failing
heart suffers from insufﬁcient oxidative metabolism and favors glucoseFig. 2.Kaplan–Meier event curves for CHFwith low (b13.03 μg/mL) or high (≥13.03 μg/mL)
2-oxoglutarate Levels.
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of the tricarboxylic acid cycle may decrease ﬂux through the tricarbox-
ylic acid cycle and overﬂow into the circulation [3,22]. 2-Oxoglutarate is
a major intermediate metabolite of the tricarboxylic acid cycle, as well
as a classical product of overﬂow in intermediate metabolite [23,24].
The amount of this overﬂow was increased when CHF occurred, which
caused the elevation of 2-oxoglutarate. The question as to whether the
elevation of 2-oxoglutarate is maladaptive or adaptive is still unsolved
and whether 2-oxoglutarate is the reporter of the metabolic switch
from fatty acid to glucose is also not known, but the signiﬁcant association
between 2-oxoglutarate and MEE observed in our study showed that
2-oxoglutarate can reﬂect MEE in spite of the origin of 2-oxoglutarate.
In the current study, our results were consistent with a prior re-
port, which showed that 2-oxoglutarate was signiﬁcantly increased
in CHF patients [3]. More importantly, we highlight that the increase
of 2-oxoglutarate was correlated with disturbed cardiac energy me-
tabolism; patients with higher MEE values had signiﬁcantly elevated
2-oxoglutarate levels. In particular, we found that the levels of 2-
oxoglutarate varied signiﬁcantly in different MEE groups, especially
in the MEE 4 group, which was increased by about 2 fold of the mean
levels of all CHF patients. This may be due to the fact that, at the mild
stage of CHF, the substrate was provided mainly by the free fatty
acid and mitochondrial function might be preserved despite the
metabolic alterations in substrate oxidation [25], so the amounts of
2-oxoglutarate overﬂow into the circulation increased slightly.
With the deterioration of CHF and the elevation of MEE, associated
with mitochondrial abnormalities and difﬁculties in ATP transport,
both fatty acid and glucose oxidation reduced and oxygen could be
partially used to generate superoxide anion [21], which may cause sig-
niﬁcant alterations in the permeability of cardiomyocyte membranes,
resulting in a dramatic increase of 2-oxoglutarate overﬂowing into the
circulation. According to the deﬁnition of biomarkers made by the
National Institute of Health [26] and three criteria for the appraisal of
novel biomarkers [27], 2-oxoglutarate added some new information
to CHF and energy metabolism and it can help the clinician to manage
patients and be measured easily. In this view, 2-oxoglutarate could be
a potential indicator of MEE and an effective marker assessing the
severity of CHF objectively.4.3. Predictive roles of 2-oxoglutarate on prognosis of CHF
Furthermore, we found that all causemortality and recurrent hospital
admission due to CHFwere associated with higher 2-oxoglutarate levels.
Theseﬁndings suggested that 2-oxoglutaratemay be useful in identifying
high risk outpatients with CHF. To our knowledge, no evidence was
provided to prove whether the signiﬁcant elevation of 2-oxoglutarate in
serious CHF was maladaptive or adaptive, our results showed that high
2-oxoglutarate levels meant the elevation of MEE and the adverse prog-
nosis. Considering that 2-oxoglutarate may be the biomarker of MEE,
this was consistent with the previous results that patients with elevated
MEE had high cardiovascular mortality [12]. HeW et al. [28] had demon-
strated that 2-oxoglutarate was a ligand of the GPR99 G-protein coupled
receptor thatmay regulate the renin–angiotensin system and it is also in-
volved in angiogenesis and growth by changing the expression of VEGF
receptor-1 and placental growth factor [29]. In this view, 2-oxoglutarate
may also be an important player in the pathogenesis of CHF.
Hepatic congestion and abnormal glucose metabolismwere often
accompanied with CHF [30]. So markers of liver dysfunction and
glucose metabolism may affect the levels of 2-oxoglutarate in CHF
patients. However, our results showed that 2-oxoglutarate was not
associated with fasting blood glucose, postprandial blood glucose,
hemoglobin A1c, alanine aminotransferase and aspartate amino-
transferase. This indicated that the increase of 2-oxoglutarate in
CHF patients was not a result of liver dysfunction or abnormal glucose
metabolism.4.4. Limitations
Several limitations of our study should be discussed. First, because
2-oxoglutarate is also abundant in the kidney [31], we do not know
whether 2-oxoglutarate can still reﬂect the levels of MEE and the
severity of CHF in patients with renal dysfunction. Second, according
to our study, 2-oxoglutarate can reﬂect the severity of CHF, but
different causes of CHF exist in our study and whether they affect the
levels of 2-oxoglutarate is unclear. Assessment between 2-oxoglutarate
and the causes of CHF would help to deﬁne their associations and effects
on cardiac metabolism in the future. Third, our current results were from
a relative short-term follow-up duration. The study of 2-oxoglutarate for
long-termprognosis in CHF patients is still undergoing and it is necessary
to validate this work.
5. Conclusion
Increased serum 2-oxoglutarate levels are associated with higher
MEE and adverse outcomes in CHF patients. These results suggest that
2-oxoglutarate could be a goodbiomarker ofMEE and can reﬂect clinical
severity and short-term outcome of CHF.
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